Evaluation of the capital market legislation's provisions on collateral
2020
0 görüntülenme
0 i̇ndirme
Danışman: Prof. Dr. Mehmet Bahtiyar
Özet (EN)
The financial transactions have gained value as a result of world-wide economical development and increasing popularity of internet usage. With the increase in transactions, product range has been widened in the capital market and additionally; because of the fascilitator effects of the internet on market, transactions have become doable even in the international market. When both the existing state of financial transactions and the worldwide experience of crisis have been generally taken into consideration, a need for legal arrangement in our country has emerged in order to ensure the efficient and productive works in financial sector and avert the risks that system has generated. Thus, there have been arrangements on financial transactions at national and international levels. In this study, how the regulations on financial transactions are determined and reflected in Turkish law concerning the taken collaterals from capital market transactions is examined.
Yazar
Müge Altınay
Kurum
Bu Yayına Nasıl Atıf Yapılır
Müge Altınay (Master Thesis). Evaluation of the capital market legislation's provisions on collateral, 2020, Yeditepe University.
Lisans
Tüm Hakları Saklıdır
Bu eser belirtilen lisans koşulları altında paylaşılmaktadır.
Yeditepe University tezlerinden daha fazlası
- Studies on cyclodextrin complexation of a poorly water soluble anti-hyperlipidemic drug, tablet formulation and characterization(2021)
- Washington ambassadors in Turkish-US relations (1927-1960)(2023)
- Metamorphosis of female voices: A study of the violation of women in Greek and Roman mythology and feminist rewritings reclaiming the narrative(2022)
- Knowledge distillation with foundation models for image segmentation(2023)
- The relationship between machiavelism, grandiose and vulnerable narcissism, and loneliness among white collar workers(2023)
- Evaluation of drug-drug interaction checkers along clinically relevant adverse drug events in oncology and hematology pediatric patients(2023)